PAUL N CLARK
CIK 1222248 · Chairman, CEO & President · last filed 2021-04-05
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$36.18M
Companies
7
Total Filings
69
Lifetime Open-Market Net
-$386.8K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AGEN | Director | — | $7.93 | — | $0 | 3 | 2021-04-05 |
| KEYS | Director | 73,620 | $312.31 | $22.99M | $0 | 10 | 2021-03-23 |
| A | Director | 95,234 | $138.50 | $13.19M | -$2.46M | 28 | 2021-03-22 |
| BIOLASE, INC (BIOL) Delisted | Director | 113 | $0.02 | $2 | $2.07M | 13 | 2017-07-03 |
| AMYLIN PHARMACEUTICALS INC (AMLN) Delisted | Director | 4,908 | — | — | $0 | 11 | 2012-04-13 |
| Talecris Biotherapeutics Holdings Corp. (TLCR) Delisted | Director | 12,715 | — | — | $0 | 1 | 2010-04-05 |
| ICOS CORP (ICOS) Delisted | Chairman, CEO & President | 0 | — | — | $0 | 2 | 2007-01-30 |
Recent Filings · Page 2 of 7
69 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-09-14 | A | Sell (S) | −2,876 | -$197.3K | EDGAR |
| 2018-03-26 | KEYS | Grant (A) | +9,061 | $0 | EDGAR |
| 2018-03-23 | A | Grant (A) | +2,876 | $194.0K | EDGAR |
| 2017-07-03 | BIOLASE, INC (BIOL) Delisted | Conv (C) | +156,300 | $193.8K | EDGAR |
| 2017-05-30 | A | Sell (S) | −3,866 | -$228.3K | EDGAR |
| 2017-05-12 | BIOLASE, INC (BIOL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-05-10 | BIOLASE, INC (BIOL) Delisted | Exer (M) | +96,250 | $0 | EDGAR |
| 2017-04-19 | BIOLASE, INC (BIOL) Delisted | Buy (P) | — | $0 | EDGAR |
| 2017-03-20 | KEYS | Grant (A) | +11,407 | $445.1K | EDGAR |
| 2017-03-17 | A | Grant (A) | +3,866 | $205.1K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.